National Health Investors, Inc. (NHI) Q2 2025 Earnings Call Transcript

National Health Investors (NHI) reported a strong Q2 2025, exceeding expectations and prompting a second upward revision to its normalized FFO guidance for 2025 to $4.80 per share, an 8.1% year-over-year increase, alongside its first dividend hike in four years. This outperformance was driven by accelerated acquisitions and exceptional growth in its Senior Housing Operating Portfolio (SHOP) NOI, which surged over 29% and will expand further with the recent transition of seven properties, significantly increasing SHOP's contribution to consolidated NOI. NHI maintains a robust balance sheet with a 3.9x net debt to adjusted EBITDA, providing ample liquidity to fund an active investment pipeline focused on accretive senior housing and SHOP opportunities, underscoring a strategic shift towards higher-growth operational investments.

Analysis

National Health Investors (NHI) reported a robust second quarter for 2025, marked by performance that surpassed internal expectations and led to a second upward revision of its full-year guidance. The company increased its normalized FFO per share guidance midpoint by $0.09 to $4.80, projecting an 8.1% year-over-year growth, and announced a 2.2% dividend increase, the first in four years. This outperformance is underpinned by a strategic pivot towards its Senior Housing Operating Portfolio (SHOP), which saw same-store NOI surge over 29% YoY, driven by record RevPOR growth of 3.7% and margin expansion to 26.9%. This shift is accelerating with the transition of seven properties into the SHOP structure, a move expected to increase annualized SHOP NOI by 57% and raise the portfolio's contribution to nearly 10% of consolidated NOI. The growth strategy is supported by a strong balance sheet, with net debt to adjusted EBITDA at a low 3.9x and liquidity of approximately $760 million, providing ample capacity to fund an active acquisition pipeline of nearly $500 million focused on senior housing. While the lease renegotiation with top tenant NHC remains a key variable, NHC's improved corporate coverage of 4.16x provides a solid foundation for the ongoing discussions.

Key Decisions for Investors

• Given the company's successful execution and aggressive pivot, investors should closely monitor the integration of the newly transitioned SHOP assets and the execution of its $350 million incremental pipeline, as this is the primary driver of the company's re-rated growth outlook.
• The upcoming NHC lease renegotiation represents a significant catalyst; while NHC's strong coverage is positive, the final terms and any associated asset dispositions will be critical in determining long-term portfolio quality and cash flow stability.
• With leverage at a low 3.9x, well below the target range, investors should assess the company's capital allocation strategy, particularly its mix of equity and debt for funding its growth pipeline, as efficient financing will be crucial to realizing guided FFO growth.
• The combination of a second guidance raise, a dividend hike after a four-year hiatus, and a clear strategy toward higher-growth operational assets may warrant a re-evaluation of NHI's valuation relative to healthcare REIT peers with significant SHOP exposure.